AI assistant
Immunocore Holdings plc — Director's Dealing 2024
Jan 2, 2024
31805_dirs_2024-01-02_f087b36d-9a4f-4d3f-b181-d430a2b4d416.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Immunocore Holdings plc (IMCR)
CIK: 0001671927
Period of Report: 2024-01-02
Reporting Person: Herbst Roy Steven (Director)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Share Option (Right to Buy) | $26.00 | 2031-02-03 | Ordinary Shares (10620) | Direct | |
| Share Option (Right to Buy) | $25.83 | 2032-05-11 | Ordinary Shares (14176) | Direct | |
| Share Option (Right to Buy) | $58.69 | 2033-05-15 | Ordinary Shares (8676) | Direct |
Footnotes
F1: 25% of the shares subject to the option award vested on February 4, 2022, and 6.25% of the shares subject to the option award vested or shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
F2: 25% of the shares subject to the option award vested on May 12, 2023, and 6.25% of the shares subject to the option award vested or shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
F3: 100% of the shares subject to the option award shall vest on May 16, 2024, subject to the Reporting Person's continuous service through such vesting date.